Identified proteins may represent viable intervention or pharmacological targets to prevent, reverse or slow type 2 diabetes progression, and further research is needed to pursue these targets (Diabetologia)
Diabetes News
Category: Pharmay
Abbott is developing a new category of consumer biowearables called Lingo
Lingo is designed to track key signals in the body – such as glucose, ketones, and lactate – to help people better understand their general health and take action
Novo Nordisk to cease distribution of Tresiba® in Germany
Novo Nordisk announce that the company has decided to cease distribution of its once-daily basal insulin Tresiba® (insulin degludec) in Germany following a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds
New Government report shows UK continues to lag in access to new medicines
The Government’s new Life Science Competitiveness Indicators – the publication which shows how well the UK performs internationally compared to other countries in the life sciences sector – shows that the UK continues to lag internationally in providing patients with access to new, innovative medicines (ABPI)
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
Eli Lilly and Company and Adocia announce a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes
Adaptive pathways: a future approach to bring new medicines to patients?
Scientists argue that scientific and political changes will make adaptive pathways the preferred approach to make new treatments available (European Medicines Agency)
Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Japan is the first country with a regulatory filing for omarigliptin. Worldwide, Merck is supporting omarigliptin with a clinical development program that includes nine Phase 3 clinical trials involving approximately 7,500 patients with type 2 diabetes in support of planned regulatory filings (Merck)
The Access to Medicine Index 2014
The fourth Access to Medicine Index report provides a finely detailed picture of how the world’s 20 largest research-based pharmaceutical companies address access to medicine. (Access to Medicine Foundation)
New study to prevent type 1 diabetes planned for Diamyd Medical’s diabetes vaccine
A new study is planned for the Diamyd® diabetes vaccine that will comprise 80 children with high risk of presenting with type 1 diabetes. The aim is to test whether the diabetes vaccine can prevent or delay the onset in the children (Diamyd)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements (Oramed Pharmaceuticals)
Sanofi Diabetes is on a mission to support children, parents and carers of children with type 1 diabetes through gaming
The New Mission T1D app, created by Sanofi Diabetes to address the need for greater understanding of T1D amongst children, parents and carers, friends and in the school environment is now available, free of charge, from the Apple UK store (Sanofi)
Mitsubishi Tanabe and AstraZeneca announce research collaboration in diabetic nephropathy
The three-year research collaboration will develop small molecule candidates from their respective portfolios (Mitsubishi Tanabe)
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015 (MannKind)
The price of medicines
Continuing an open and honest debate – Alison Clough, ABPI Executive Director – Commercial UK, responds to NICE Chairman, David Haslam’s, interview with Pharmafocus last month
Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes
The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition (Sanofi)
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
MSD and Samsung Bioepis announce that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon (Merck)
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance
AstraZeneca announce that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance (AstraZeneca)
Oramed Announces Successful FDA Phase 2a Clinical Trial Results
A Phase 2a clinical trial for ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints (Oramed)
Bristol-Myers Squibb – Sale of Its Diabetes Business
Bristol-Myers Squibb Company announce that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca (Bristol-Myers Squibb)
Bristol, AstraZeneca withdraw diabetes drug in Germany
Bristol-Myers Squibb and AstraZeneca said they would pull a new diabetes drug from the German market because they had failed to agree on a price with a body of medical insurers. The decision to stop marketing oral drug dapagliflozin in Germany comes just a day after it was endorsed by an advisory panel to the U.S. Food and Drug Administration (Reuters)
Glycosmedia is also available as an App: